About
Ophthalmic keratolytics
Areas of Focus
Categories
Small Molecule PharmaceuticalDrug Delivery & FormulationMiddle East
Clinical Trials (6)
View allTotal Trials
6
As Lead Sponsor
6
As Collaborator
0
Total Enrollment
977
By Phase
PHASE3: 1PHASE2: 4PHASE2/PHASE3: 1
By Status
COMPLETED: 5ACTIVE_NOT_RECRUITING: 1
Clinical Trials Pipeline6 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
Today
Hover over trial bars to see details
Recent Trials
NCT06329791Lead Sponsor
A Phase 3 Study to Evaluate AZR-MD-001 in Patients with Abnormal Meibomian Gland Function and Dry Eye Disease (DED)
PHASE3Active, not recruiting
500 participants
Started: May 28, 2024 · Completed: Nov 30, 2025
NCT05548491Lead Sponsor
Safety, Tolerability and Pharmacodynamics of AZR-MD-001 in Contact Lens Discomfort (CLD)
PHASE2Completed
67 participants
Started: Nov 10, 2022 · Completed: Oct 13, 2023
NCT04391959Lead Sponsor
Evaluation of AZR-MD-001 in Patients With Meibomian Gland Dysfunction (MGD)
PHASE2Completed
31 participants
Started: Jul 17, 2020 · Completed: Jan 6, 2021
NCT04314362Lead Sponsor
Methods to Enhance AZR-MD-001 for Meibomian Gland Dysfunction (MGD)
PHASE2/PHASE3Completed
32 participants
Started: Jul 14, 2020 · Completed: Jan 6, 2021
NCT03972501Lead Sponsor
An Evaluation of AZR-MD-001 as Treatment for Meibomian Gland Dysfunction (MGD) or Contact Lens Discomfort (CLD)
PHASE2Completed
26 participants
Started: Oct 4, 2019 · Completed: Dec 11, 2020
Locations (1)
Headquarters
Tel Aviv, Israel
Map
Loading map...